SARS Nucleocapsid (a.a. 1-422) [His] (DAG1351)

Recombinant SARS Nucleocapsid (a.a. 1-422) from E. coli [His]

Product Overview
Recombinant SARS-CoV Nucleocapsid protein fusioned to His Tag was expressed in E. coli and purified by three-step procedure using affinity Ni-NTA chromatography and size exclusion chromatography before and after refolding.
Nature
Recombinant
Tag/Conjugate
His
Alternative Names
SARS Nucleocapsid; SARS; SARS NP; SARS Nucleoprotein; SARS N Protein
Procedure
None
Purity
Greater than 95% as determined by SDS-PAGE.
Format
Lyophilized
Buffer
Sterile filtered and lyophilized from 0.5 mg/ml in 0.05 M Acetate buffer pH4.
Preservative
None
Storage
2-8°C short term, -20°C long term
Introduction
A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive stranded RNA approximately 27 to 31kb in length.
Keywords
SARS Nucleocapsid; SARS; SARS NP; SARS Nucleoprotein; SARS N Protein

Citations


Have you cited DAG1351 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Hsueh, PR; Kao, CL; et al. SARS antibody test for serosurveillance. EMERGING INFECTIOUS DISEASES 10:1558-1562(2004).
Czub, M; Weingartl, H; et al. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. VACCINE 23:2273-2279(2005).

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket